XERIS BIOPHARMA HOLDINGS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$14.32 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$14.32M, a 155.28% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $25.90M, a 82.17% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $14.22M, a 32.81% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $21.16M, a 53.38% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$14.32M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $25.90M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $14.22M 10-K · filed 2025-03-06 | |
| 2022-12-31 | $21.16M 10-K · filed 2025-03-06 | |
| 2021-12-31 | $45.39M 10-K · filed 2024-03-06 | -$45.39M 10-K · filed 2022-03-11 |
| 2020-12-31 | -$23.54M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |